REGN17372
/ Regeneron
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 27, 2026
R17372-HM-2493: A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myeloma
(clinicaltrialsregister.eu)
- P1 | N=26 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals Inc.
First-in-human • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
April 16, 2026
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1/2 | N=150 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Hematological Malignancies • Multiple Myeloma • Oncology
March 07, 2026
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1/2 | N=150 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals
First-in-human • New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 3
Of
3
Go to page
1